| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Yuanyi Wei, Xian Wang, Zhiling Yu, Wenqi Zhou, Lili Wang, Fei Qin, Chunxia Wang, Lianbing Ho. Efficacy and Mechanism of Action of Yiru Tiaojing Granule Against Hyperprolactinemia In Vitro and In Vivo. Planta medica. vol 81. issue 14. 2016-06-27. PMID:26252831. |
the dopamine d2 receptor in hyperprolactinemia rat models was analyzed by immunohistochemistry. |
2016-06-27 |
2023-08-13 |
rat |
| Yuanyi Wei, Xian Wang, Zhiling Yu, Wenqi Zhou, Lili Wang, Fei Qin, Chunxia Wang, Lianbing Ho. Efficacy and Mechanism of Action of Yiru Tiaojing Granule Against Hyperprolactinemia In Vitro and In Vivo. Planta medica. vol 81. issue 14. 2016-06-27. PMID:26252831. |
the results suggested that yiru tiaojing granule was effective against hyperprolactinemia, and the activation of the dopamine d2 receptor, which was related to the second messenger cyclic adenosine monophosphate and protein kinase a, might be the potential mechanism. |
2016-06-27 |
2023-08-13 |
rat |
| A Arduc, F Gokay, S Isik, U Ozuguz, G Akbaba, Y Tutuncu, D Berker, F K Kucukler, Y Aydin, S Gule. Retrospective comparison of cabergoline and bromocriptine effects in hyperprolactinemia: a single center experience. Journal of endocrinological investigation. vol 38. issue 4. 2016-06-20. PMID:25421155. |
patients with hyperprolactinemia who require medical therapy are typically treated with dopamine agonists (das). |
2016-06-20 |
2023-08-13 |
Not clear |
| Hussein Halabi, Israa Mull. Rheumatoid Arthritis, Kartagener's Syndrome, and Hyperprolactinemia: Who Started It? Case reports in rheumatology. vol 2016. 2016-02-23. PMID:26904347. |
furthermore, hyperprolactinemia has been hypothesized to mirror ra disease activity and case reports of treatment with dopamine agonists have led to the speculation of whether or not they represent a new line of experimental treatment in the future. |
2016-02-23 |
2023-08-13 |
Not clear |
| Milica Medic-Stojanoska, Tijana Icin, Ivana Pletikosic, Ivana Bajkin, Jovanka Novakovic-Paro, Edita Stokic, Dragan T Spasic, Branka Kovacev-Zavisic, Ludovico Abenavol. Risk factors for accelerated atherosclerosis in young women with hyperprolactinemia. Medical hypotheses. vol 84. issue 4. 2015-12-03. PMID:25649851. |
the hypothesis is that hyperprolactinemia can cause metabolic and inflammatory changes which are associated with accelerated atherosclerotic process, but the treatment of hyperprolactinemia with dopamine agonists, leads to reversibility of these processes. |
2015-12-03 |
2023-08-13 |
Not clear |
| D Iacovazzo, L De Marini. Treatment of hyperprolactinemia in post-menopausal women: pros. Endocrine. vol 48. issue 1. 2015-11-11. PMID:25112228. |
hyperprolactinemia is a recognized cause of secondary osteoporosis, and treatment with dopamine agonists can lead to improved bmd. |
2015-11-11 |
2023-08-13 |
Not clear |
| D Iacovazzo, L De Marini. Treatment of hyperprolactinemia in post-menopausal women: pros. Endocrine. vol 48. issue 1. 2015-11-11. PMID:25112228. |
here, we review data potentially favouring medical treatment with dopamine agonists in post-menopausal women diagnosed with hyperprolactinemia. |
2015-11-11 |
2023-08-13 |
Not clear |
| Christos C Zoubouli. [Treatment of acne with antiandrogens--an evidence-based review]. Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG. vol 1. issue 7. 2015-10-27. PMID:16295039. |
antiandrogens can be classified based on their mechanism of action as androgen receptor blockers, inhibitors of circulating androgens by affecting ovarian function (oral contraceptives), inhibitors of circulating androgens by affecting the pituitary (gonadotropin-releasing hormone agonists and dopamine agonists in hyperprolactinemia), inhibitors of adrenal function, and inhibitors of peripheral androgen metabolism (5alpha-reductase inhibitors, inhibitors of other enzymes). |
2015-10-27 |
2023-08-12 |
Not clear |
| Jimena Ferraris, Sandra Zárate, Gabriela Jaita, Florence Boutillon, Marie Bernadet, Julien Auffret, Adriana Seilicovich, Nadine Binart, Vincent Goffin, Daniel Piser. Prolactin induces apoptosis of lactotropes in female rodents. PloS one. vol 9. issue 5. 2015-02-27. PMID:24859278. |
we showed that acute hyperprolactinemia induced in ovariectomized rats using prl injection or dopamine antagonist treatment rapidly increased apoptosis and decreased proliferation specifically of prl producing cells (lactotropes), suggesting a direct regulation of these cell responses by prl. |
2015-02-27 |
2023-08-13 |
mouse |
| Domenico De Berardis, Michele Fornaro, Nicola Serroni, Stefano Marini, Monica Piersanti, Marilde Cavuto, Alessandro Valchera, Monica Mazza, Gabriella Girinelli, Felice Iasevoli, Giampaolo Perna, Giovanni Martinotti, Massimo Di Giannantoni. Treatment of antipsychotic-induced hyperprolactinemia: an update on the role of the dopaminergic receptors D2 partial agonist aripiprazole. Recent patents on endocrine, metabolic & immune drug discovery. vol 8. issue 1. 2015-01-22. PMID:24372345. |
aripiprazole is a drug with partial agonist activity at the level of dopamine receptors d2, which may be effective for antipsychotic- induced hyperprolactinemia. |
2015-01-22 |
2023-08-12 |
Not clear |
| Maya Barake, A Eden Evins, Luke Stoeckel, Gladys N Pachas, Lisa B Nachtigall, Karen K Miller, Beverly M K Biller, Nicholas A Tritos, Anne Klibansk. Investigation of impulsivity in patients on dopamine agonist therapy for hyperprolactinemia: a pilot study. Pituitary. vol 17. issue 2. 2014-11-13. PMID:23504371. |
investigation of impulsivity in patients on dopamine agonist therapy for hyperprolactinemia: a pilot study. |
2014-11-13 |
2023-08-12 |
human |
| Laura D Ratner, Susana B Rulli, Ilpo T Huhtaniem. Genetically modified mouse models addressing gonadotropin function. Reproductive biology. vol 14. issue 1. 2014-11-06. PMID:24607250. |
in addition, we describe the role of hyperprolactinemia as the main cause of infertility and the phenotypic abnormalities in these mice, and the use of dopamine agonists bromocriptine and cabergoline to normalize these conditions. |
2014-11-06 |
2023-08-12 |
mouse |
| Kojiro Hashimoto, Norio Sugawara, Masamichi Ishioka, Kazuhiko Nakamura, Norio Yasui-Furukor. The effects of additional treatment with terguride, a partial dopamine agonist, on hyperprolactinemia induced by antipsychotics in schizophrenia patients: a preliminary study. Neuropsychiatric disease and treatment. vol 10. 2014-09-04. PMID:25187719. |
the effects of additional treatment with terguride, a partial dopamine agonist, on hyperprolactinemia induced by antipsychotics in schizophrenia patients: a preliminary study. |
2014-09-04 |
2023-08-13 |
Not clear |
| Ignacio Bernabeu, Felipe F Casanuev. Metabolic syndrome associated with hyperprolactinemia: a new indication for dopamine agonist treatment? Endocrine. vol 44. issue 2. 2014-07-01. PMID:23975607. |
metabolic syndrome associated with hyperprolactinemia: a new indication for dopamine agonist treatment? |
2014-07-01 |
2023-08-12 |
Not clear |
| Deanna L Kelly, Heidi J Wehring, Amber K Earl, Kelli M Sullivan, Faith B Dickerson, Stephanie Feldman, Robert P McMahon, Robert W Buchanan, Dale Warfel, William R Keller, Bernard A Fischer, Joo-Cheol Shi. Treating symptomatic hyperprolactinemia in women with schizophrenia: presentation of the ongoing DAAMSEL clinical trial (Dopamine partial Agonist, Aripiprazole, for the Management of Symptomatic ELevated prolactin). BMC psychiatry. vol 13. 2014-05-08. PMID:23968123. |
treating symptomatic hyperprolactinemia in women with schizophrenia: presentation of the ongoing daamsel clinical trial (dopamine partial agonist, aripiprazole, for the management of symptomatic elevated prolactin). |
2014-05-08 |
2023-08-12 |
Not clear |
| W M Drake, C E Stiles, T A Howlett, A A Toogood, J S Bevan, R P Steed. A cross-sectional study of the prevalence of cardiac valvular abnormalities in hyperprolactinemic patients treated with ergot-derived dopamine agonists. The Journal of clinical endocrinology and metabolism. vol 99. issue 1. 2014-03-12. PMID:24187407. |
concern exists in the literature that the long-term use of ergot-derived dopamine agonist drugs for the treatment of hyperprolactinemia may be associated with clinically significant valvular heart disease. |
2014-03-12 |
2023-08-12 |
Not clear |
| Christina S Kalkavoura, Ioannis Michopoulos, Periklis Arvanitakis, Pitsa Theodoropoulou, Konstantina Dimopoulou, Errikos Tzebelikos, Lefteris Lykoura. Effects of cabergoline on hyperprolactinemia, psychopathology, and sexual functioning in schizophrenic patients. Experimental and clinical psychopharmacology. vol 21. issue 4. 2014-03-10. PMID:23834553. |
we conducted this 6-month, parallel-group study to prospectively investigate the effects of the dopamine agonist cabergoline on sexual dysfunction in clinically stable patients with schizophrenia (dsm-iv, ap 194) and hyperprolactinemia (prl > 20 ng/ml for men and prl > 25 ng/ml for women). |
2014-03-10 |
2023-08-12 |
Not clear |
| Takashi Tsuboi, Robert R Bies, Takefumi Suzuki, David C Mamo, Bruce G Pollock, Ariel Graff-Guerrero, Masaru Mimura, Hiroyuki Uchid. Hyperprolactinemia and estimated dopamine D2 receptor occupancy in patients with schizophrenia: analysis of the CATIE data. Progress in neuro-psychopharmacology & biological psychiatry. vol 45. 2014-02-26. PMID:23727135. |
hyperprolactinemia and estimated dopamine d2 receptor occupancy in patients with schizophrenia: analysis of the catie data. |
2014-02-26 |
2023-08-12 |
Not clear |
| M Victoria Recouvreux, Lara Lapyckyj, M Andrea Camilletti, M Clara Guida, Ana Ornstein, Daniel B Rifkin, Damasia Becu-Villalobos, Graciela Díaz-Torg. Sex differences in the pituitary transforming growth factor-β1 system: studies in a model of resistant prolactinomas. Endocrinology. vol 154. issue 11. 2014-01-08. PMID:24008346. |
ablation of the dopamine d2 receptor gene (drd2(-/-)) in mice leads to a sexually dimorphic phenotype of hyperprolactinemia and pituitary hyperplasia, which is stronger in females. |
2014-01-08 |
2023-08-12 |
mouse |
| M K Vanklompenberg, R Manjarin, J F Trott, H F McMicking, R C Hove. Late gestational hyperprolactinemia accelerates mammary epithelial cell differentiation that leads to increased milk yield. Journal of animal science. vol 91. issue 3. 2013-10-25. PMID:23296835. |
we hypothesized that inducing hyperprolactinemia in primiparous gilts during late gestation by administering the dopamine antagonist domperidone (dom) would increase mg epithelial cell proliferation and differentiation, subsequent milk yield, and piglet growth. |
2013-10-25 |
2023-08-12 |
Not clear |